Initial results of cyberknife treatment for recurrent previously irradiated head and neck cancer

Kengo Himei, Kuniaki Katsui, Atsushi Yoshida, Mitsuhiro Takemoto, Masahiro Kuroda, Susumu Kanazawa, Kengo Sato, Yoshimi Baba, Rie Omori, Mitsuhiro Inoue, Yoshio Hiraki

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the efficacy of CyberKnife for recurrent previously irradiated head and neck cancer. Materials and Methods: Thirty-one patients with recurrent previously irradiated head and neck cancer were treated with a CyberKnife from July 1999 to March 2002 at Okayama Kyokuto Hospital were retrospectively studied. The accumulated dose was 28-80 Gy (median 60 Gy). The interval between CyberKnife treatment and previous radiotherapy was 0.4-429.5 months (median 16.3 months). Primary lesions were nasopharynx: 7, maxillary sinus: 6, tongue: 5, ethmoid sinus: 3, and others: 1. The pathology was squamous cell carcinoma: 25, adenoid cystic carcinoma: 4, and others: 2. Symptoms were pain: 8, and nasal bleeding: 2. The prescribed dose was 15.0-40.3 Gy (median 32.3 Gy) as for the marginal dose. Results: The response rate (CR+PR) and local control rate (CR+PR+NC) was 74% and 94% respectively. Pain disappeared for 4 cases, relief was obtained for 4 cases and no change for 2 cases and nasal bleeding disappeared for 2 cases for an improvement of symptoms. An adverse effects were observed as mucositis in 5 cases and neck swelling in one case. Conclusions: Prognosis of recurrent previously irradiated head and neck cancer was estimated as poor. Our early experience shows that CyberKnife is expected to be feasible treatment for recurrent previously irradiated head and neck cancer, and for the reduction adverse effects and maintenance of useful QOL for patients.

Original languageEnglish
Pages (from-to)139-144
Number of pages6
JournalJournal of JASTRO
Volume15
Issue number2
Publication statusPublished - Jun 2003

Fingerprint

Head and Neck Neoplasms
Epistaxis
Ethmoid Sinus
Pain
Adenoid Cystic Carcinoma
Mucositis
Nasopharynx
Maxillary Sinus
Therapeutics
Tongue
Squamous Cell Carcinoma
Neck
Radiotherapy
Maintenance
Pathology

Keywords

  • CyberKnife
  • Recurrent head and neck cancer
  • Reirrardiation
  • Stereotactic irradiation

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Initial results of cyberknife treatment for recurrent previously irradiated head and neck cancer. / Himei, Kengo; Katsui, Kuniaki; Yoshida, Atsushi; Takemoto, Mitsuhiro; Kuroda, Masahiro; Kanazawa, Susumu; Sato, Kengo; Baba, Yoshimi; Omori, Rie; Inoue, Mitsuhiro; Hiraki, Yoshio.

In: Journal of JASTRO, Vol. 15, No. 2, 06.2003, p. 139-144.

Research output: Contribution to journalArticle

Himei, K, Katsui, K, Yoshida, A, Takemoto, M, Kuroda, M, Kanazawa, S, Sato, K, Baba, Y, Omori, R, Inoue, M & Hiraki, Y 2003, 'Initial results of cyberknife treatment for recurrent previously irradiated head and neck cancer', Journal of JASTRO, vol. 15, no. 2, pp. 139-144.
Himei, Kengo ; Katsui, Kuniaki ; Yoshida, Atsushi ; Takemoto, Mitsuhiro ; Kuroda, Masahiro ; Kanazawa, Susumu ; Sato, Kengo ; Baba, Yoshimi ; Omori, Rie ; Inoue, Mitsuhiro ; Hiraki, Yoshio. / Initial results of cyberknife treatment for recurrent previously irradiated head and neck cancer. In: Journal of JASTRO. 2003 ; Vol. 15, No. 2. pp. 139-144.
@article{061a049ff4034facbec0cef6e5d02881,
title = "Initial results of cyberknife treatment for recurrent previously irradiated head and neck cancer",
abstract = "Purpose: To evaluate the efficacy of CyberKnife for recurrent previously irradiated head and neck cancer. Materials and Methods: Thirty-one patients with recurrent previously irradiated head and neck cancer were treated with a CyberKnife from July 1999 to March 2002 at Okayama Kyokuto Hospital were retrospectively studied. The accumulated dose was 28-80 Gy (median 60 Gy). The interval between CyberKnife treatment and previous radiotherapy was 0.4-429.5 months (median 16.3 months). Primary lesions were nasopharynx: 7, maxillary sinus: 6, tongue: 5, ethmoid sinus: 3, and others: 1. The pathology was squamous cell carcinoma: 25, adenoid cystic carcinoma: 4, and others: 2. Symptoms were pain: 8, and nasal bleeding: 2. The prescribed dose was 15.0-40.3 Gy (median 32.3 Gy) as for the marginal dose. Results: The response rate (CR+PR) and local control rate (CR+PR+NC) was 74{\%} and 94{\%} respectively. Pain disappeared for 4 cases, relief was obtained for 4 cases and no change for 2 cases and nasal bleeding disappeared for 2 cases for an improvement of symptoms. An adverse effects were observed as mucositis in 5 cases and neck swelling in one case. Conclusions: Prognosis of recurrent previously irradiated head and neck cancer was estimated as poor. Our early experience shows that CyberKnife is expected to be feasible treatment for recurrent previously irradiated head and neck cancer, and for the reduction adverse effects and maintenance of useful QOL for patients.",
keywords = "CyberKnife, Recurrent head and neck cancer, Reirrardiation, Stereotactic irradiation",
author = "Kengo Himei and Kuniaki Katsui and Atsushi Yoshida and Mitsuhiro Takemoto and Masahiro Kuroda and Susumu Kanazawa and Kengo Sato and Yoshimi Baba and Rie Omori and Mitsuhiro Inoue and Yoshio Hiraki",
year = "2003",
month = "6",
language = "English",
volume = "15",
pages = "139--144",
journal = "Journal of JASTRO",
issn = "1040-9564",
publisher = "Editorial Board of JASTRO",
number = "2",

}

TY - JOUR

T1 - Initial results of cyberknife treatment for recurrent previously irradiated head and neck cancer

AU - Himei, Kengo

AU - Katsui, Kuniaki

AU - Yoshida, Atsushi

AU - Takemoto, Mitsuhiro

AU - Kuroda, Masahiro

AU - Kanazawa, Susumu

AU - Sato, Kengo

AU - Baba, Yoshimi

AU - Omori, Rie

AU - Inoue, Mitsuhiro

AU - Hiraki, Yoshio

PY - 2003/6

Y1 - 2003/6

N2 - Purpose: To evaluate the efficacy of CyberKnife for recurrent previously irradiated head and neck cancer. Materials and Methods: Thirty-one patients with recurrent previously irradiated head and neck cancer were treated with a CyberKnife from July 1999 to March 2002 at Okayama Kyokuto Hospital were retrospectively studied. The accumulated dose was 28-80 Gy (median 60 Gy). The interval between CyberKnife treatment and previous radiotherapy was 0.4-429.5 months (median 16.3 months). Primary lesions were nasopharynx: 7, maxillary sinus: 6, tongue: 5, ethmoid sinus: 3, and others: 1. The pathology was squamous cell carcinoma: 25, adenoid cystic carcinoma: 4, and others: 2. Symptoms were pain: 8, and nasal bleeding: 2. The prescribed dose was 15.0-40.3 Gy (median 32.3 Gy) as for the marginal dose. Results: The response rate (CR+PR) and local control rate (CR+PR+NC) was 74% and 94% respectively. Pain disappeared for 4 cases, relief was obtained for 4 cases and no change for 2 cases and nasal bleeding disappeared for 2 cases for an improvement of symptoms. An adverse effects were observed as mucositis in 5 cases and neck swelling in one case. Conclusions: Prognosis of recurrent previously irradiated head and neck cancer was estimated as poor. Our early experience shows that CyberKnife is expected to be feasible treatment for recurrent previously irradiated head and neck cancer, and for the reduction adverse effects and maintenance of useful QOL for patients.

AB - Purpose: To evaluate the efficacy of CyberKnife for recurrent previously irradiated head and neck cancer. Materials and Methods: Thirty-one patients with recurrent previously irradiated head and neck cancer were treated with a CyberKnife from July 1999 to March 2002 at Okayama Kyokuto Hospital were retrospectively studied. The accumulated dose was 28-80 Gy (median 60 Gy). The interval between CyberKnife treatment and previous radiotherapy was 0.4-429.5 months (median 16.3 months). Primary lesions were nasopharynx: 7, maxillary sinus: 6, tongue: 5, ethmoid sinus: 3, and others: 1. The pathology was squamous cell carcinoma: 25, adenoid cystic carcinoma: 4, and others: 2. Symptoms were pain: 8, and nasal bleeding: 2. The prescribed dose was 15.0-40.3 Gy (median 32.3 Gy) as for the marginal dose. Results: The response rate (CR+PR) and local control rate (CR+PR+NC) was 74% and 94% respectively. Pain disappeared for 4 cases, relief was obtained for 4 cases and no change for 2 cases and nasal bleeding disappeared for 2 cases for an improvement of symptoms. An adverse effects were observed as mucositis in 5 cases and neck swelling in one case. Conclusions: Prognosis of recurrent previously irradiated head and neck cancer was estimated as poor. Our early experience shows that CyberKnife is expected to be feasible treatment for recurrent previously irradiated head and neck cancer, and for the reduction adverse effects and maintenance of useful QOL for patients.

KW - CyberKnife

KW - Recurrent head and neck cancer

KW - Reirrardiation

KW - Stereotactic irradiation

UR - http://www.scopus.com/inward/record.url?scp=0041573195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041573195&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0041573195

VL - 15

SP - 139

EP - 144

JO - Journal of JASTRO

JF - Journal of JASTRO

SN - 1040-9564

IS - 2

ER -